VAS
AZN icon

Vestmark Advisory Solutions’s AstraZeneca AZN Stock Holding History

Vestmark Advisory Solutions’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.7M Buy
84,737
+3,760
+5% +$725K 0.19% 120
2025
Q4 		$14.9M Buy
80,977
+46,593
+136% +$8.17M 0.2% 94
2025
Q3 		$5.28M Sell
34,384
-7,816
-19% -$1.18M 0.1% 202
2025
Q2 		$5.9M Buy
42,200
+8,180
+24% +$1.15M 0.09% 178
2025
Q1 		$5M Buy
34,020
+18,729
+122% +$2.71M 0.13% 209
2024
Q4 		$2M Buy
15,291
+3,114
+26% +$436K 0.07% 259
2024
Q3 		$1.9M Buy
12,177
+239
+2% +$38.6K 0.07% 250
2024
Q2 		$1.86M Buy
11,938
+248
+2% +$37.3K 0.08% 246
2024
Q1 		$1.58M Sell
11,690
-1,546
-12% -$205K 0.07% 268
2023
Q4 		$1.78M Buy
13,236
+1,059
+9% +$138K 0.09% 236
2023
Q3 		$1.65M Sell
12,177
-16,983
-58% -$2.32M 0.12% 195
2023
Q2 		$4.17M Sell
29,160
-3,443
-11% -$507K 0.16% 167
2023
Q1 		$4.53M Sell
32,603
-287
-0.9% -$38.6K 0.2% 139
2022
Q4 		$4.46M Sell
32,890
-796
-2% -$99.8K 0.22% 127
2022
Q3 		$3.69M Buy
33,686
+3,645
+12% +$462K 0.21% 130
2022
Q2 		$3.97M Buy
30,041
+8,813
+42% +$1.16M 0.23% 111
2022
Q1 		$2.82M Buy
21,228
+1,397
+7% +$168K 0.16% 156
2021
Q4 		$2.31M Sell
19,831
-1,293
-6% -$152K 0.13% 199
2021
Q3 		$2.54M Sell
21,124
-1,370
-6% -$159K 0.17% 145
2021
Q2 		$2.69M Buy
22,494
+3,044
+16% +$334K 0.19% 131
2021
Q1 		$1.93M Buy
19,450
+1,279
+7% +$129K 0.17% 162
2020
Q4 		$1.82M Buy
18,171
+1,052
+6% +$111K 0.2% 139
2020
Q3 		$1.88M Buy
17,119
+477
+3% +$53.1K 0.25% 123
2020
Q2 		$1.76M Sell
16,642
-2,533
-13% -$262K 0.27% 108
2020
Q1 		$1.71M Sell
19,175
-373
-2% -$35.1K 0.33% 77
2019
Q4 		$1.95M Sell
19,548
-1,318
-6% -$124K 0.4% 84
2019
Q3 		$1.86M Sell
20,866
-649
-3% -$56.3K 0.3% 97
2019
Q2 		$1.78M Buy
21,515
+385
+2% +$30.2K 0.3% 93
2019
Q1 		$1.71M Buy
+21,130
New +$1.67M 0.3% 91

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Vestmark Advisory Solutions's AZN Position: Q1 2026 in Review

Vestmark Advisory Solutions increased its AstraZeneca (AZN) stake by 4.6% in Q1 2026, buying an estimated $725K and bringing the position to 84,737 shares worth $16.7M. The position accounts for 0.19% of the portfolio, ranked #120.

Vestmark Advisory Solutions first reported a position in AZN in Q1 2019 and has held it in 29 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Vestmark Advisory Solutions held 84,737 shares of AstraZeneca worth $16.7M as of Q1 2026.
  • Vestmark Advisory Solutions bought 3,760 AstraZeneca shares in Q1 2026, an estimated $725K.
  • AstraZeneca made up 0.19% of Vestmark Advisory Solutions's portfolio in Q1 2026, its #120 holding.
  • Vestmark Advisory Solutions first reported a position in AstraZeneca in Q1 2019 and has held it in 29 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q1 2026, filed 15 May 2026.